참고문헌
- Hsieh MY, Lin ZY, Chen SH, et al (2011). Risk factors for the leakage of chemotherapeutic agents into systemic circulation after transcatheter arterial chemoembolization of hepatocellular carcinoma. Kaohsiung J Med Sci, 27, 431-6. https://doi.org/10.1016/j.kjms.2011.06.001
- Lavi O, Skinner J, Gottesman MM (2014). Network features suggest new hepatocellular carcinoma treatment strategies. BMC Syst Biol, 8, 88. https://doi.org/10.1186/s12918-014-0088-0
- Gaur A, Jewell DA, Liang Y, et al (2007). Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res, 67, 2456-68. https://doi.org/10.1158/0008-5472.CAN-06-2698
- Shi XB, Tepper CG, deVere White RW (2008). Cancerous miRNAs and their regulation. Cell Cycle, 7, 1529-38. https://doi.org/10.4161/cc.7.11.5977
- Giovannetti E, Erozenci A, Smit J, et al (2012). Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol, 81, 103-22. https://doi.org/10.1016/j.critrevonc.2011.03.010
- Hu Q, Gong JP, Li J, et al (2014). Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells. Asian Pac J Cancer Prev, 15, 5137-42. https://doi.org/10.7314/APJCP.2014.15.13.5137
- Wang HJ, Guo YQ, Tan G, et al (2013). miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype. J Cell Biochem, 114, 2248-57. https://doi.org/10.1002/jcb.24574
- Yamaguchi T, Nakajima N, Nakamura I, et al (2013). Preclinical anticancer effects and toxicologic assessment of hepatic artery infusion of fine-powder cisplatin with lipiodol in vivo. Drug Discov Ther, 7, 201-8.
- Yang JX, Luo Y, Qiu HM, et al (2009). Characterization and resistance mechanisms of cisplatin-resistant human hepatocellular carcinoma cell line. Saudi Med J, 30, 35-40.
- Chen Y, Fu LL, Wen X, et al (2014). Oncogenic and tumor suppressive roles of microRNAs in apoptosis and autophagy. Apoptosis, 19, 1177-89. https://doi.org/10.1007/s10495-014-0999-7
- Robertson NM, Yigit MV (2014). The role of microRNA in resistance to breast cancer therapy. Wiley Interdiscip Rev RNA.
- Bao LJ, Jaramillo MC, Zhang ZB, et al (2014). Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma. Int J Clin Exp Pathol, 7, 1502-13.
- Niture SK, Kaspar JW, Shen J, et al (2010). Nrf2 signaling and cell survival. Toxicol Appl Pharmacol, 244, 37-42. https://doi.org/10.1016/j.taap.2009.06.009
- Sangokoya C, Telen MJ, Chi JT (2010). microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood, 116, 4338-48. https://doi.org/10.1182/blood-2009-04-214817
- He X, Ma Q (2010). Critical cysteine residues of Kelch-like ECH-associated protein 1 in arsenic sensing and suppression of nuclear factor erythroid 2-related factor 2. J Pharmacol
피인용 문헌
- miRNA Influences in NRF2 Pathway Interactions within Cancer Models vol.2015, pp.2090-021X, 2015, https://doi.org/10.1155/2015/143636
- MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells vol.35, pp.1, 2016, https://doi.org/10.1186/s13046-016-0296-0
- MicroRNA-340 promotes the tumor growth of human gastric cancer by inhibiting cyclin G2 vol.36, pp.2, 2016, https://doi.org/10.3892/or.2016.4876
- MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATβ in osteosarcoma vol.50, pp.5, 2017, https://doi.org/10.1590/1414-431x20176359
- Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance vol.8, pp.3, 2017, https://doi.org/10.3390/genes8030095
- microRNA-340 Suppresses Tumorigenic Potential of Prostate Cancer Cells by Targeting High-Mobility Group Nucleosome-Binding Domain 5 vol.35, pp.1, 2016, https://doi.org/10.1089/dna.2015.3021
- SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis vol.37, pp.9, 2018, https://doi.org/10.1038/s41388-017-0029-7
- Non-coding RNA in drug resistance of hepatocellular carcinoma vol.38, pp.5, 2018, https://doi.org/10.1042/BSR20180915
- The Network of Non-coding RNAs in Cancer Drug Resistance vol.8, pp.2234-943X, 2018, https://doi.org/10.3389/fonc.2018.00327
- NRAL mediates cisplatin resistance in hepatocellular carcinoma via miR-340-5p/Nrf2 axis pp.1873-961X, 2018, https://doi.org/10.1007/s12079-018-0479-x
- Identification of microRNA Biomarkers of Response to Neoadjuvant Chemoradiotherapy in Esophageal Adenocarcinoma Using Next Generation Sequencing vol.25, pp.9, 2018, https://doi.org/10.1245/s10434-018-6626-z
- miR-340 alleviates chemoresistance of osteosarcoma cells by targeting ZEB1 vol.29, pp.5, 2018, https://doi.org/10.1097/CAD.0000000000000614
- confers adverse clinical outcome in patients with acute myeloid leukemia vol.234, pp.4, 2019, https://doi.org/10.1002/jcp.27178
- MicroRNA replacement therapy in cancer pp.00219541, 2019, https://doi.org/10.1002/jcp.28058
- MicroRNA-mediated redox regulation modulates therapy resistance in cancer cells: clinical perspectives pp.2211-3436, 2019, https://doi.org/10.1007/s13402-018-00421-z
- The role and mechanisms of action of microRNAs in cancer drug resistance vol.11, pp.1, 2019, https://doi.org/10.1186/s13148-018-0587-8
- The Role of Nrf2 in Liver Disease: Novel Molecular Mechanisms and Therapeutic Approaches vol.9, pp.1663-9812, 2018, https://doi.org/10.3389/fphar.2018.01428